PDIA6: A Potential Drug Target and Biomarker (G10130)

Target Name: PDIA6

NCBI ID: G10130

PDIA6

PDIA6: A Potential Drug Target and Biomarker

PDIA6, also known as 2-phenyl-1-propanethiol (2-PPT), is a protein that is expressed in various tissues, including the brain, heart, and kidneys. It is a key player in the regulation of cell growth and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a potential drug target, PDIA6 has generated a lot of interest in recent years, and research is ongoing to determine its efficacy and safety as a therapeutic intervention.

PDIA6 functions as a negative regulator of the TGF-β pathway, which is a well-established pathway that plays a crucial role in the development and maintenance of tissues and organs. The TGF-β pathway is a complex signaling pathway that is involved in the regulation of cell growth, differentiation, and survival. It is activated in response to various signaling cues, including the presence of growth factors, and it regulates the production of extracellular matrix (ECM) components, such as collagen, that contribute to tissue stiffness and integrity.

PDIA6 is a key regulator of the TGF-β pathway, and it is involved in the negative regulation of the pathway. It does this by binding to the TGF-β receptor, which is a transmembrane protein that is involved in the regulation of cell growth and differentiation. PDIA6 is thought to work by inhibiting the activity of the TGF-β receptor, thereby preventing the activation of the pathway and the production of ECM components.

PDIA6 has been shown to be involved in a number of physiological processes in the body, including cell growth, differentiation, and survival. It has been shown to be involved in the regulation of neuronal development and the maintenance of neuronal networks, and it has been implicated in the development and progression of a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

PDIA6 has also been shown to be involved in the regulation of inflammation, and it has been implicated in the development and progression of a number of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. It has been shown to be involved in the regulation of fibrosis, which is the process by which cells produce excessive amounts of extracellular matrix components, and it has been implicated in the development of a number of diseases, including cancer.

PDIA6 has also been shown to be involved in the regulation of cell death, and it has been implicated in the development and progression of a number of diseases, including neurodegenerative diseases, cancer, and trauma. It has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death, and it has been implicated in the development and progression of a number of diseases.

PDIA6 is a protein that has been shown to be involved in a number of physiological processes in the body, and it has been implicated in a number of diseases. As a potential drug target, PDIA6 has generated a lot of interest in recent years, and research is ongoing to determine its efficacy and safety as a therapeutic intervention. Further research is needed to fully understand the role of PDIA6 in the regulation of cell growth and differentiation, and to determine its potential as a drug target.

Protein Name: Protein Disulfide Isomerase Family A Member 6

Functions: May function as a chaperone that inhibits aggregation of misfolded proteins (PubMed:12204115). Negatively regulates the unfolded protein response (UPR) through binding to UPR sensors such as ERN1, which in turn inactivates ERN1 signaling (PubMed:24508390). May also regulate the UPR via the EIF2AK3 UPR sensor (PubMed:24508390). Plays a role in platelet aggregation and activation by agonists such as convulxin, collagen and thrombin (PubMed:15466936)

The "PDIA6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDIA6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets